{"id":513303,"date":"2024-11-18T00:00:00","date_gmt":"2024-11-18T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfon0008-2024-biopharma-myelodysplastic-syndromes-niche-rare-disease-landscape-forecast-us-eu5-2024\/"},"modified":"2026-03-31T10:27:55","modified_gmt":"2026-03-31T10:27:55","slug":"nrlfon0008-2024-biopharma-myelodysplastic-syndromes-niche-rare-disease-landscape-forecast-us-eu5-2024","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfon0008-2024-biopharma-myelodysplastic-syndromes-niche-rare-disease-landscape-forecast-us-eu5-2024\/","title":{"rendered":"Myelodysplastic Syndromes | Niche &#038; Rare Disease Landscape &#038; Forecast | US\/EU5 | 2024"},"content":{"rendered":"<p>Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem cell disorders that result in cytopenia and the risk of progression to acute myeloid leukemia (AML). Bristol Myers Squibb \/ Acceleron\u2019s Reblozyl (luspatercept) for lower-risk adult MDS, Astex Pharmaceuticals\u2019 Inqovi (decitabine and cedazuridine) for higher-risk adult MDS and refractory MDS, Geron Corporation\u2019s Rytelo (imetelstat) for low- to intermediate-1-risk MDS with transfusion-dependent anemia, and Servier\u2019s Tibsovo (ivosidenib) for relapsed or refractory MDS with an IDH1 mutation are effective treatments. Other pharmacological approaches to managing the disease (e.g., growth factor stimulants [e.g., erythropoietin-stimulating agents], lenalidomide [Revlimid, generics], hypomethylating agents [e.g., azacitidine]) are designed to ameliorate the symptoms and extend patients\u2019 survival, although there is a significant gap in the treatment of refractory disease. The MDS pipeline is robust, and several projected market entrants are poised to penetrate both lower- and higher-risk subpopulations.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>How will the launches of Reblozyl (luspatercept), Inqovi (decitabine and cedazuridine), Rytelo (imetelstat), and Tibsovo (ivosidenib) change MDS treatment?<\/li>\n<li>What is the commercial outlook for current and emerging therapies for MDS?<\/li>\n<li>Which emerging therapies are most likely to have an impact on the MDS therapy market by 2033?<\/li>\n<li>How will the size of the MDS population change by 2033?<\/li>\n<\/ul>\n<p><strong>Geography:<\/strong> United States and EU5<\/p>\n<p><strong>Primary research:<\/strong> Six country-specific interviews with thought-leading hematologists supported by survey data collected for this study<\/p>\n<p><strong>Epidemiology:<\/strong> Diagnosed incident and diagnosed prevalent cases of MDS by country, drug-treated prevalent and incident cases of MDS, diagnosed incident and prevalent cases of MDS by morphology, and diagnosed prevalent cases by prognostic risk<\/p>\n<p><strong>Forecast: <\/strong>Drug-level sales and patient share of key MDS therapies through 2033<\/p>\n<p><strong>Drug treatments:<\/strong> Coverage of key current and emerging therapies<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Niche &#038; Rare Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Key feature<\/strong><\/p>\n<p>Niche &#038; Rare Disease Landscape &#038; Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-513303","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-myelodysplastic-syndromes","biopharma-geography-us","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/513303","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/513303\/revisions"}],"predecessor-version":[{"id":575887,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/513303\/revisions\/575887"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=513303"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}